J&J Built a Lung Cancer Empire. Two Underdogs Just Crashed the Gates.

The drug already showed promise in the REZILIENT1 Phase 2b study, posting a 35.2% overall response rate in the primary efficacy population of previously treated patients. That earlier dataset was strong enough for the FDA to accept a New Drug Application in April 2026, with a decision date set for February 27, 2027.

Now the Phase 3 first-line data add a much bigger feather to the cap. The REZILIENT3 trial enrolled patients across multiple countries who had never been treated for their advanced disease. Zipalertinib plus platinum-based chemo beat chemotherapy alone on progression-free survival (PFS), which measures how long patients live without their cancer getting worse. The companies called the benefit "statistically significant and clinically meaningful," though they're saving the specific numbers for a medical conference.

Why J&J Should Be Paying Attention

J&J isn't just watching from the sidelines here. Their drug Rybrevant (amivantamab) is already approved for EGFR exon 20 insertion lung cancer, both as a single agent after chemo failure and as a first-line combination with carboplatin and pemetrexed. J&J has also been aggressively expanding amivantamab's reach into the much larger common EGFR mutation market, pairing it with their oral drug lazertinib (branded as Lazcluze) and claiming superior survival over osimertinib.

So J&J has a two-pronged strategy: dominate the big EGFR market and hold the exon 20 insertion turf. Zipalertinib's Phase 3 win threatens the second prong directly.

The competitive question boils down to this: would doctors rather give patients a targeted oral pill, or an IV bispecific antibody? Amivantamab requires infusions and carries infusion-related reactions. Zipalertinib is a pill you take at home. Convenience matters enormously when efficacy is in the same ballpark.

Wall Street's Verdict: Cautiously Bullish

Analysts didn't waste time weighing in. William Blair's Matt Phipps pointed out that the trial was designed to detect a 40% reduction in the risk of progression or death at final analysis. Stopping early at an interim look suggests the actual benefit may be even larger than that threshold.

Cantor Fitzgerald's Li Watsek said the result "raises the competitive bar," though she cautioned it's "premature to assess the magnitude of the competitive threat" without full data. Fair enough; we're still flying partially blind.

On the stock side, Morgan Stanley maintained a Buy rating with a $30 target on Cullinan, citing the clinical progress and upside from the Taiho partnership.

The Partnership Behind the Scenes

Speaking of that partnership: it's a big one. Taiho paid $275 million upfront in 2022 to co-develop and co-commercialize zipalertinib in the U.S. The deal includes up to $130 million more in regulatory milestones, with $30 million tied to a second-line approval and $100 million linked to a first-line green light. U.S. costs and profits are split 50/50, while Taiho handles markets outside the U.S. and China.

For a company Cullinan's size, that's a massive war chest. It means they don't have to go it alone against J&J's commercial juggernaut.

The Bigger Picture

The EGFR-targeted NSCLC market is projected to grow from roughly $6.6 billion in 2025 to $14.2 billion by 2036 across major markets. That growth isn't just coming from one drug; it's coming from a wave of new entrants. Dizal's sunvozertinib (branded Zegfrovy) is already approved for EGFR exon 20 insertion lung cancer. ArriVent BioPharma's firmonertinib has pivotal data coming soon. Antibody-drug conjugates are entering the mix, too.

But in the exon 20 insertion corner specifically, the field is narrower. And zipalertinib just planted its flag with the strongest Phase 3 evidence yet for a targeted oral therapy in this space.

The full dataset will tell us whether this is a solid win or a knockout. For now, J&J still holds the crown, but the challengers have arrived with a credible claim to the throne. And in oncology, competition isn't just good for business; it's good for patients who desperately need better options.

The Vaccine That Isn't for a Virus

Moderna and Merck just delivered the first-ever positive Phase 3 result for an mRNA cancer vaccine, sending Moderna's market cap soaring by $45 billion in a single day. The personalized melanoma vaccine could reshape oncology and rewrite Moderna's post-COVID narrative.